Cargando…

Antiviral resistance markers in influenza virus sequences in Mexico, 2000–2017

BACKGROUND: Influenza causes high rates of morbidity and mortality. Genetic variability of influenza viruses generates resistance to antivirals, which are of two types, since they act on two different viral targets: adamantanes, which block the M2 ion channel, and the neuraminidase (NA) inhibitors....

Descripción completa

Detalles Bibliográficos
Autores principales: Toledo-Rueda, William, Rosas-Murrieta, Nora H, Muñoz-Medina, José E, González-Bonilla, César R, Reyes-Leyva, Julio, Santos-López, Gerardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188218/
https://www.ncbi.nlm.nih.gov/pubmed/30349332
http://dx.doi.org/10.2147/IDR.S153154
_version_ 1783363184886808576
author Toledo-Rueda, William
Rosas-Murrieta, Nora H
Muñoz-Medina, José E
González-Bonilla, César R
Reyes-Leyva, Julio
Santos-López, Gerardo
author_facet Toledo-Rueda, William
Rosas-Murrieta, Nora H
Muñoz-Medina, José E
González-Bonilla, César R
Reyes-Leyva, Julio
Santos-López, Gerardo
author_sort Toledo-Rueda, William
collection PubMed
description BACKGROUND: Influenza causes high rates of morbidity and mortality. Genetic variability of influenza viruses generates resistance to antivirals, which are of two types, since they act on two different viral targets: adamantanes, which block the M2 ion channel, and the neuraminidase (NA) inhibitors. METHODS: In Mexico, the available studies on the antiviral resistance of circulating influenza strains are scarce, so this work undertook an analysis of the Mexican sequences reported in public gene banks to perform a systematic analysis of the antiviral resistance markers on both M2 and NA. In all, 284 M2 sequences and 423 NA sequences were retrieved from three genetic databases (sequences from 2000 to 2017 were considered). RESULTS: The resistance markers to M2 blockers were present in 100% of H1N1 pdm2009, 83.6% of H3N2, and 5.8% of seasonal H1N1 sequences. Two resistance markers conferring resistance to NA inhibitors were present in seasonal H1N1 sequences, H275Y (50.0%) and N70S (33.3%). None of these viruses had both resistance markers, which are associated with oseltamivir resistance. The more frequent resistance marker in H1N1 pdm2009 NA sequences was H275Y, present in 3.6%, while S247N was present in 0.30%. Only one of the resistance-associated markers (Q136K) in NA (1.5%) was present in the analyzed H3N2 sequences, while sequences of influenza B virus did not present resistance markers to NA inhibitors. Some influenza A H1N1 pdm2009 sequences (1.8%) presented resistance markers to both M2 and NA. CONCLUSION: Based on the present analysis, 7.1% of the all serotypes of influenza virus A sequences analyzed in Mexico from 2000 to 2017 have mutations conferring resistance to NA inhibitors. Because of this, and the limited availability of influenza drugs, it is necessary to increase the epidemiological surveillance, including molecular analysis, which will provide data such as the presence of changes associated with antiviral resistance.
format Online
Article
Text
id pubmed-6188218
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-61882182018-10-22 Antiviral resistance markers in influenza virus sequences in Mexico, 2000–2017 Toledo-Rueda, William Rosas-Murrieta, Nora H Muñoz-Medina, José E González-Bonilla, César R Reyes-Leyva, Julio Santos-López, Gerardo Infect Drug Resist Original Research BACKGROUND: Influenza causes high rates of morbidity and mortality. Genetic variability of influenza viruses generates resistance to antivirals, which are of two types, since they act on two different viral targets: adamantanes, which block the M2 ion channel, and the neuraminidase (NA) inhibitors. METHODS: In Mexico, the available studies on the antiviral resistance of circulating influenza strains are scarce, so this work undertook an analysis of the Mexican sequences reported in public gene banks to perform a systematic analysis of the antiviral resistance markers on both M2 and NA. In all, 284 M2 sequences and 423 NA sequences were retrieved from three genetic databases (sequences from 2000 to 2017 were considered). RESULTS: The resistance markers to M2 blockers were present in 100% of H1N1 pdm2009, 83.6% of H3N2, and 5.8% of seasonal H1N1 sequences. Two resistance markers conferring resistance to NA inhibitors were present in seasonal H1N1 sequences, H275Y (50.0%) and N70S (33.3%). None of these viruses had both resistance markers, which are associated with oseltamivir resistance. The more frequent resistance marker in H1N1 pdm2009 NA sequences was H275Y, present in 3.6%, while S247N was present in 0.30%. Only one of the resistance-associated markers (Q136K) in NA (1.5%) was present in the analyzed H3N2 sequences, while sequences of influenza B virus did not present resistance markers to NA inhibitors. Some influenza A H1N1 pdm2009 sequences (1.8%) presented resistance markers to both M2 and NA. CONCLUSION: Based on the present analysis, 7.1% of the all serotypes of influenza virus A sequences analyzed in Mexico from 2000 to 2017 have mutations conferring resistance to NA inhibitors. Because of this, and the limited availability of influenza drugs, it is necessary to increase the epidemiological surveillance, including molecular analysis, which will provide data such as the presence of changes associated with antiviral resistance. Dove Medical Press 2018-10-11 /pmc/articles/PMC6188218/ /pubmed/30349332 http://dx.doi.org/10.2147/IDR.S153154 Text en © 2018 Toledo-Rueda et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Toledo-Rueda, William
Rosas-Murrieta, Nora H
Muñoz-Medina, José E
González-Bonilla, César R
Reyes-Leyva, Julio
Santos-López, Gerardo
Antiviral resistance markers in influenza virus sequences in Mexico, 2000–2017
title Antiviral resistance markers in influenza virus sequences in Mexico, 2000–2017
title_full Antiviral resistance markers in influenza virus sequences in Mexico, 2000–2017
title_fullStr Antiviral resistance markers in influenza virus sequences in Mexico, 2000–2017
title_full_unstemmed Antiviral resistance markers in influenza virus sequences in Mexico, 2000–2017
title_short Antiviral resistance markers in influenza virus sequences in Mexico, 2000–2017
title_sort antiviral resistance markers in influenza virus sequences in mexico, 2000–2017
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188218/
https://www.ncbi.nlm.nih.gov/pubmed/30349332
http://dx.doi.org/10.2147/IDR.S153154
work_keys_str_mv AT toledoruedawilliam antiviralresistancemarkersininfluenzavirussequencesinmexico20002017
AT rosasmurrietanorah antiviralresistancemarkersininfluenzavirussequencesinmexico20002017
AT munozmedinajosee antiviralresistancemarkersininfluenzavirussequencesinmexico20002017
AT gonzalezbonillacesarr antiviralresistancemarkersininfluenzavirussequencesinmexico20002017
AT reyesleyvajulio antiviralresistancemarkersininfluenzavirussequencesinmexico20002017
AT santoslopezgerardo antiviralresistancemarkersininfluenzavirussequencesinmexico20002017